Skip to main content
STAR COMBO PHARMA LIMITED logo

STAR COMBO PHARMA LIMITED — Investor Relations & Filings

Ticker · S66 ISIN · AU0000004798 ASX Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2022-02-22 Interim / Quarterly Rep…
Country AU Australia
Listing ASX S66

About STAR COMBO PHARMA LIMITED

https://www.starcombo.com.au

Star Combo Pharma Limited specializes in the development, manufacturing, and distribution of vitamins, dietary supplements, and skincare products. The organization operates Therapeutic Goods Administration (TGA) licensed facilities, offering comprehensive Original Equipment Manufacturing (OEM) and Original Design Manufacturing (ODM) services. Its product portfolio encompasses a wide range of health and beauty solutions marketed under proprietary brands, including Costar, Living Healthy, Amax, and J&K. The company focuses on delivering premium health products to diverse markets, leveraging technical expertise in formulation and large-scale production. By maintaining rigorous quality control standards and providing end-to-end manufacturing solutions, the entity serves as a strategic partner for businesses seeking customized health and wellness products.

Recent filings

Filing Released Lang Actions
S66 Dec 2021 Half Year Report and Financial Statements 22 pages 464.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D HALF YEAR REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2021' and includes detailed financial statements, directors' report, auditor's independence declaration, and consolidated statement of profit or loss and financial position for the half year period. It references ASX Listing Rule 4.2A, which pertains to half yearly reports. The content includes comprehensive financial data and management commentary for a half year period, not just an announcement or summary. Therefore, this document is a comprehensive interim/quarterly financial report for a period shorter than a full fiscal year, matching the definition of an Interim / Quarterly Report (IR).
2022-02-22 English
S66 Dec 2021 Half Year Results Commentary 2 pages 154.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 23 February 2022, titled 'Star Combo Pharma 1H22 Result'. It provides detailed financial and operational highlights for the first half of the financial year 2022, including revenue figures, cash flow, order book status, and outlook. The content includes substantive financial data and analysis for a half-year period, which aligns with the characteristics of an Interim / Quarterly Report (IR). The document is over 6,000 characters, indicating it is a full report rather than a brief announcement or a report publication notice. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-02-22 English
S66 - Q2 FY22 Business Update 2 pages 176.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 January 2022, titled 'Star Combo Pharma Quarterly Business Update' and provides detailed operational and financial highlights for the quarter ended 31 December 2021 (Q2 FY22). It includes revenue figures, order details, cash flow information, and outlook commentary. The content is comprehensive and covers a quarterly period with substantive financial data and business updates. It is not a brief summary or a simple announcement of a report publication, nor is it a transcript, audit, or management change notice. The document fits the definition of an Interim / Quarterly Report (IR) as it provides a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and analysis.
2022-01-30 English
Notification of cessation of securities - S66 4 pages 24.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the cessation (cancellation) of securities for STAR COMBO PHARMA LIMITED. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following the changes. There is no financial data, no report attached or referenced, and the document is an announcement of a change in the company's capital structure related to securities. This fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as cancellations.
2021-12-16 English
S66 Cancellation of Shares 3 pages 223.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 30 November 2021 regarding a share cancellation resolution passed at the AGM held on 23 November 2021. It includes details of share cancellation and changes to the company's share capital structure. The document also contains an attached ASIC Form 484, which is a regulatory form used to notify changes to company details, specifically share cancellations and share structure changes. The document is relatively short (4048 characters) and primarily serves as an announcement of the share cancellation and the filing of Form 484 with ASIC. It does not contain comprehensive financial data or detailed financial statements. Therefore, it is best classified as a Share Issue/Capital Change announcement (SHA) because it relates to changes in the company's share capital structure due to share cancellations.
2021-11-29 English
S66 - CEO Presentation to 2021 AGM 9 pages 1.3MB
AGM Information Classification · 95% confidence The document is titled 'STAR COMBO PHARMA LIMITED Annual General Meeting 23 November 2021 CEO Presentation' and contains detailed business updates, financial highlights, operational performance, and outlook typically presented at an AGM. It includes sections on key themes for FY21, business division updates, Q1 FY22 trading update, and achievements and outlook, which are characteristic of an investor presentation given at an AGM. The document length is about 5102 characters, which is consistent with a presentation rather than a full annual report or earnings release. There is no indication that this is a full annual report (10-K) or an earnings release (ER), nor is it a regulatory filing or announcement. The presence of slides and pictures (intentionally omitted) further supports that this is a presentation document. Therefore, the most appropriate classification is 'AGM Information' (AGM-R).
2021-11-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.